Session: 503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Translational Research, CHIP, GVHD, Diseases, Immune Disorders, Myeloid Malignancies, Biological Processes, Molecular biology, Pathogenesis
To examine whether mutations in DNMT3A affect T cell function leading to GVHD and anti-leukemic effects, we used a murine Dnmt3aR878H/+ model harboring the clinically equivalent point mutation most seen in hematological malignancies (R882H, Loberg et. al. Leukemia 2019). We found that up to 80% of Dnmt3aR878H/+ mice developed a severe ulcerative dermatitis characterized by a hyperplastic epidermis with increased lymphocytic infiltration (p<.02). Further profiling of T cells isolated from the skin of wild type (WT) and mutant mice revealed that Dnmt3aR878H/+ mice had an increase in CD4 effector memory T cells (p<.04). In comparison to the skin, the frequency of T cells in the spleen and thymus was similar between WT and Dnmt3aR878H/+ mice. However, the percentage of activated T cells increased significantly in mutant mice (p<.01). Splenic T cells from Dnmt3aR878H/+ had decreased naïve CD4 and CD8 cells with increased frequency in CD4+ effector memory T cells (p<.001) and CD8+ central memory T cells (p<.02).
To evaluate whether the activation/inflammatory phenotype was due to Dnmt3a-dependent changes in DNA methylation and gene expression, methylation and transcriptome profiling were performed on CD4+ andCD8+ T cells isolated from WT and Dnmt3aR878H/+ mice. Methylation analysis revealed that over 80% of differentially methylated probes (DMPs) were hypomethylated in Dnmt3aR878H/+ mutant T cells, with 3X more DMPs in CD4+ T cells compared to CD8+ T cells. Although there were more upregulated than downregulated genes in CD4+ and CD8+ T cells isolated from Dnmt3aR878H/+ mice, we found 3X more upregulated genes in Dnmt3aR878H/+ CD4+ T cells. Integration of methylation and gene expression analyses showed that 61% of genes were both upregulated and hypomethylated in CD4+ Dnmt3aR878H/+ T cells. Pathways enriched in Dnmt3aR878H/+ CD4+ T cells included interferon g and IL-2 signaling. Single cell RNAseq analysis of WT and Dnmt3aR878H/+ splenic T cells and found that Dnmt3aR878H/+ cells were less abundant in naïve cell clusters, more abundant in effector and memory clusters, and displayed differentially expressed genes involved in T cell activation and effector function.
To functionally assess T cells isolated from Dnmt3aR878H/+ mice, we adoptively transferred naïve CD4+ or CD8+ T cells into NSG mice. We found that mice that received Dnmt3aR878H/+ CD4+ T cells showed a significant increase in activated T cell expansion and developed more severe skin, liver, lung, and gut GVHD compared to WT CD4+ T cell recipients. Similar but less dramatic differences were observed in CD8+ adoptive T cell transfer experiments. In parallel, we evaluated the response of Dnmt3aR878H/+ T cells when challenged with a murine leukemia cell line and found Dnmt3aR878H/+ T cells had increased killing when compared to WT cells in vitro (p<.04). In vivo analysis showed that Dnmt3aR878H/+ mice had a lower leukemic burden (p<0.002) and improved survival compared to WT mice (55 vs 22 days). Single cell RNAseq was notable for increased expansion of cytotoxic CD8+ and effector CD4+ T cells in spleens of Dnmt3aR878H/+ tumor challenged mice. In conclusion, we demonstrate that Dnmt3a-mutant HSCs can give rise to persistently activated T cells that may play both pathogenic and protective roles in allogeneic transplant recipients.
Disclosures: Thomas: Immunoscape: Membership on an entity's Board of Directors or advisory committees; Cytoagents: Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Other: travel support ; Shennon Bio: Membership on an entity's Board of Directors or advisory committees; PACT Pharma: Consultancy, Other: travel support; Pfizer: Consultancy, Other: travel support; JNJ: Consultancy, Other: travel support; Illumina: Consultancy, Other: travel support; 10X genomics: Consultancy, Other: travel support; Merck: Consultancy, Other: travel support.
See more of: Oral and Poster Abstracts